CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

CinCor Pharma CINC has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD).

The figHTN-CKD trial is a randomised Phase 2 clinical trial designed to assess the safety and efficacy of Baxdrostat (CIN-107) in patients with uncontrolled hypertension and CKD.

The company anticipates initial top-line data readout for figHTN-CKD clinical trial in second half of 2023.

Mason Freeman, M.D., Chief Medical Officer, commented: "Baxdrostat is a highly selective aldosterone synthase inhibitor that can significantly reduce aldosterone levels, offering the potential to not only improve uncontrolled blood pressure in CKD patients, but also ameliorate the negative impacts of aldosterone on kidney function."

Baxdrostat (CIN-107) is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for treatment-resistant hypertension and primary aldosteronism.

CinCor Pharma shares are trading 9.7% higher midday Wednesday at $17.07. 

Posted In: Clinical Trial Patient EnrolmentBiotechHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.